Such patients are good candidates for treatment. Patients with non-regional LNs (M1a) were included on STAMPEDE. In the M1a subgroup analysis presented at ESMO 2019, there was a significant improvement in FFS (HR 0.64, 0.43-0.96) and a trend to improvement in OS (HR 0.62, 0.35-1.09) (~180 patients i...